Cambrex completes major expansion of solid form screening facility in Edinburgh

The expansion increases the company's capacity and provides its clients with larger process crystallization development, up to 20-L scale.

This major expansion project has seen the facility's total footprint doubled to 15,000 sq. ft, with existing laboratory space having been refurbished, and an additional 3,500 sq. ft of laboratory space added.

The company said it has experienced an increase in demand for its services, particularly for larger-scale crystallization projects. This expansion, therefore, increases the company's efficiency and ability to respond to these requests.

The expansion has added an additional 13 fume cupboards to the laboratory, including three that are “walk-in”, which will allow the Edinburgh team to increase capacity and provide its clients with larger process crystallization development, up to 20-L scale.

Tom Loewald, Chief Executive Officer of Cambrex, said this investment at the Edinburgh site, which is one part of the company's integrated drug substance offering, increases their flexibility to work on projects at all stages of drug development.”

Cambrex’s Edinburgh site provides solid form development services for drug substance and drug product. These include solid state investigations such as salt, co-crystal, and polymorph screening, in addition to crystallization process development and GMP analytical services.

The expert scientists at the site work on projects both as a standalone service to a range of pharmaceutical innovators, as well as liaising with other Cambrex sites to offer an integrated process development service.

The site currently has 50 employees, and the expansion will add additional laboratory space to enable the recruitment of up to 40 more scientists, with the potential for further growth in the future.